Skip to content
Ikena logo
Ikena logo

Press Releases

Press Releases

LinkedIn LinkedIn Twitter Twitter
  • Focus
  • Pipeline
  • Resources
  • Team
  • Careers
  • Contact
  • Investors
    • Corporate Profile
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Financial Filings
    • Corporate Governance
    • Investor Resources
Menu
  • Focus
  • Pipeline
  • Resources
  • Team
  • Careers
  • Contact
  • Investors
    • Corporate Profile
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Financial Filings
    • Corporate Governance
    • Investor Resources
Ikena Hero Image
  • Corporate Profile
  • Press Releases
  • Events & Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historic Price Lookup
    • Analyst Coverage
  • Financial Filings
    • SEC Filings
  • Corporate Governance
    • Documents & Charters
    • Management Team
    • Board of Directors
  • Investor Resources
    • Investor FAQs
    • Investor Email Alerts
    • Contact IR
Aug 11, 2022
Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
Jul 06, 2022
Ikena Oncology to Participate in the William Blair Biotech Focus Conference 2022
Jun 22, 2022
Ikena Oncology Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficient Mesothelioma
May 18, 2022
Ikena Oncology to Participate in Spring 2022 Investor Conferences
May 12, 2022
Ikena Oncology Reports First Quarter 2022 Financial Results and Provides a Corporate Update
May 02, 2022
Ikena Oncology and Vall d’Hebron Institute of Oncology Announce Research & Development Collaboration
Apr 28, 2022
Ikena Oncology to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
Apr 13, 2022
Ikena Appoints Jotin Marango, M.D., Ph.D., as Chief Financial Officer and Head of Corporate Development
Mar 17, 2022
Ikena Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
Mar 07, 2022
Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting
  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
  • Print Page
  • Email Alerts
  • RSS Feeds
Ikena logo

Ikena Oncology
645 Summer Street
Suite 101
Boston, MA 02210

Ikena Oncology
645 Summer Street
Suite 101
Boston, MA 02210

  • Focus
  • Pipeline
  • Resources
  • Team
  • Careers
  • Contact
  • Investors
    • Corporate Profile
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Financial Filings
    • Corporate Governance
    • Investor Resources
Menu
  • Focus
  • Pipeline
  • Resources
  • Team
  • Careers
  • Contact
  • Investors
    • Corporate Profile
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Financial Filings
    • Corporate Governance
    • Investor Resources
  • Focus
  • Pipeline
  • Resources
  • Team
  • Careers
  • Contact
  • Investors
Menu
  • Focus
  • Pipeline
  • Resources
  • Team
  • Careers
  • Contact
  • Investors
    • Corporate Profile
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Financial Filings
    • Corporate Governance
    • Investor Resources

Privacy Policy | Terms of Use | Accessibility

© 2022 Ikena Oncology.

LinkedIn LinkedIn Twitter Twitter